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France, 17 Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland,
18 Department of Information and Communication Technologies, Universitat Pompeu Fabra, Barcelona,
Spain, 19 Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Spain,
20 Department of Biochemistry and Molecular Biomedicine, Universitat de Barcelona, Barcelona, Spain,
21 Department of Social and Behavioral Science, Harvard T.H. Chan School of Public Health, Boston,
Massachusetts, United States of America, 22 Empirica Communication and Technology Research, Bonn,
Germany, 23 Departament de Matemàtiques i Informàtica, Universitat de Barcelona, Barcelona, Spain,
24 Department of Epidemiology and Biostatistics, MRC-PHE Centre for Environment and Health, School of
Public Health, Imperial College London, London, United Kingdom, 25 Unit of Primary Health Care, Oulu
University Hospital, OYS, Oulu, Finland, 26 Department of Life Sciences, College of Health and Life
Sciences, Brunel University London, London, United Kingdom, 27 Medical Faculty of the University of Zürich
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Abstract
Introduction
Depression, cardiovascular diseases and diabetes are among the major non-communicable
diseases, leading to significant disability and mortality worldwide. These diseases may
share environmental and genetic determinants associated with multimorbid patterns.
Stressful early-life events are among the primary factors associated with the development
of mental and physical diseases. However, possible causative mechanisms linking early life
stress (ELS) with psycho-cardio-metabolic (PCM) multi-morbidity are not well understood.
This prevents a full understanding of causal pathways towards the shared risk of these dis-
eases and the development of coordinated preventive and therapeutic interventions.
Methods and analysis
This paper describes the study protocol for EarlyCause, a large-scale and inter-disciplinary
research project funded by the European Union’s Horizon 2020 research and innovation
programme. The project takes advantage of human longitudinal birth cohort data, animal
studies and cellular models to test the hypothesis of shared mechanisms and molecular
pathways by which ELS shapes an individual’s physical and mental health in adulthood. The
study will research in detail how ELS converts into biological signals embedded simulta-
neously or sequentially in the brain, the cardiovascular and metabolic systems. The
research will mainly focus on four biological processes including possible alterations of the
epigenome, neuroendocrine system, inflammatome, and the gut microbiome. Life-course
models will integrate the role of modifying factors as sex, socioeconomics, and lifestyle with
the goal to better identify groups at risk as well as inform promising strategies to reverse the
possible mechanisms and/or reduce the impact of ELS on multi-morbidity development in
high-risk individuals. These strategies will help better manage the impact of multi-morbidity
on human health and the associated risk.
1. Introduction
1.1 Early life stress and psycho-cardio-metabolic multi-morbidity
The World Health Organisation has identified mental disorders, including depression, cardio-
vascular diseases and diabetes among the six major non-communicable diseases [1]. Individu-
ally, each of these groups of diseases represents a burden at the individual and population
level. Depression alone is the single largest contributor to global disability, accounting for 12%
of total years lived with disability [2] with more than 300 million individuals affected per year.
Cardiovascular diseases (CVDs) remain the prime cause of mortality worldwide, accounting
for about a third of annual deaths [3]. Finally, type 2 diabetes and related metabolic dysfunc-
tions, including obesity, are a major public health challenge, with an average prevalence of
over 8% in the general population [4]. In addition to their separate complexity, existing
research has shown important multi-morbidity between these diseases, where multi-morbidity
is defined as the co-occurrence of two or more chronic conditions [5]. Epidemiological studies
have indeed shown that for example patients experiencing depression are more likely to have
comorbid CVD [6], type 2 diabetes [7], or both [8]. However, the specific causative mecha-
nisms leading to psycho-cardio-metabolic (PCM) multi-morbidity are not well understood,
which limits the development of effective preventive and therapeutic measures.
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Recent evidence suggests that many mental and physical conditions find their origins in
exposure to stress early in life, otherwise defined as early-life-stress (ELS) [9]. ELS can be both
prenatal, such as exposure to clinically-significant depression in utero, and postnatal, such as
emotional, physical and sexual abuse or neglect in childhood, parental psychopathology and
separation, prepubertal bullying, as well as victimisation or violence by peers [10]. Growing
evidence has supported an association between ELS (both prenatal and postnatal) and the
development of the PCM conditions. Specifically, patients with a history of ELS have higher
vulnerability for depression [11], and higher risk of developing cardiovascular disease [12],
obesity [13] and type 2 diabetes [14] later in life. Prenatally, the overarching hypothesis is that
the maternal stress response is passed to the fetus, via stress hormones crossing the placenta,
which affects subsequent brain and physical development of the fetus and newborn [15]. Dur-
ing childhood, exposure to excessive levels of stress early in life can cause several biological
alterations which can ultimately favour the development of PCM multi-morbidity [16]. As
suggested by Barker’s work on the developmental origins of chronic diseases, including PCM
conditions [17], the exact predictors of the development of these diseases are to be linked with
variations of key systems during the developmental stage. Examples of key biological system
alterations due to responses to stress include hypothalamic-pituitary-adrenal (HPA) axis
changes as a response to stress [18], changes in the inflammatory response [19], microbiome
dysbiosis [20,21] and overall bio-psycho-social axis dysfunction [22]. While ELS has also been
linked to resilience in adulthood [23], our research will focus on understanding the mecha-
nisms leading to the negative consequences, in particular PCM multi-morbidity. Considering
that the prevalence of ELS, both in utero and postnatally, whether mild or severe, has reached
alarming heights [15], this area of research is essential for future disease prevention and health
promotion.
The objective of this paper is to present the EarlyCause project, a large-scale interdisciplin-
ary research that aims to infer evidence for causative mechanisms linking pre- and postnatal
ELS to PCM multi-morbidity, even decades after the exposure itself has ceased. To explain this
enduring effect, EarlyCause will seek to identify both biological mediators and environmental
moderators. With regards to biological mediators, the hypothesis is that the enduring effects of
ELS may reflect in part a “biologically embedding”, whereby ELS alters biological development
and function in a way that engenders latent vulnerability for poor health outcomes and
increased susceptibility. This is supported by the identification of numerous biological corre-
lates of ELS, and previously mentioned, including neuroendocrine dysregulation, heightened
inflammatory response, changes in gut microbiota composition, and, more recently, alter-
ations to the epigenome. The ambition of EarlyCause is to go well beyond reductionist
approaches which have traditionally investigated new biomedical knowledge while treating
disease classes, biological scales and temporal domains (e.g. childhood vs. adulthood) sepa-
rately. We will thus investigate more holistic models of the causative pathways by building on
the experience of our consortium in advanced methods such as Mendelian randomisation,
structural equation modelling, multi-omics, and machine/deep learning. We will detail below
EarlyCause objectives and hypotheses, as well as the methods that will be implemented to test
these hypotheses (see Method section).
Furthermore, the EarlyCause consortium fully understands that given the prevalence of
ELS affecting millions of mothers and children, important efforts need to be dedicated from
day one to maximising the clinical and socioeconomic impacts. As one of its core objectives,
EarlyCause will ensure that each impact is adequately assessed from clinical and non-clinical
perspectives, as to allow future exploitation of the innovation outputs. This work will be done
while taking into account the current gaps and limitations due to the single-disease frame-
works that have dominated for a very long-time research, biotech innovation and healthcare.
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1.2 Rationale and overview of the EarlyCause project
EarlyCause is the product of a collaboration between 14 participating institutions across
Europe (Table 1) and is supported by the European Union’s Horizon 2020 research and inno-
vation programme (SC1-BHC-01-2019).
EarlyCause will investigate the hypothesis that ELS, as a risk factor for depressive, cardio-
vascular and metabolic disorders individually, is a cause of multi-morbidity between these
conditions. From a biological point of view, the main hypothesis is that ELS activates a chain
of events leading to cellular, molecular, epigenetic and microbial changes from the norm. This
causative chain would ultimately trigger specific cellular and tissue phenotypes and comorbid
pathological traits in the mental, cardiovascular and metabolic domains.
To this end, EarlyCause’s overarching concept is to build upon a unique repertoire of longi-
tudinal data in humans across the lifespan and conduct mechanistic studies in established ani-
mal and cellular models to:
i. Identify the causal mechanisms linking exposure to ELS to the risk of multi-morbid symp-
toms across life;
ii. Delineate the potential molecular mechanisms underlying these causal associations;
iii. Discover new biomarkers tapping into multiple biological domains;
iv. Build integrative computational models and proof-of-concept tools for multi-morbidity
assessment.
The project will focus on four candidate families of biological pathways that have been
linked to ELS, specifically:
1. Epigenetic alterations are a presumed link between stress exposure and phenotypes. Clear
associations between early-life adverse exposure and epigenetic processes (e.g. DNA meth-
ylation) and between these epigenetic modifications and later health outcomes have been
shown both in humans [24–26] and mouse models [27].
2. HPA changes have been associated with ELS exposure [18]. Molecular components of the
HPA axis provide a relay chain across the body from the brain to the periphery, and some
Table 1. Participating institutions in the EarlyCause project.
Participant no. Participant organisation name Acronym Country
1 (Coordinator) Universitat de Barcelona UB ES
2 European Molecular Biology Laboratory EMBL DE
3 Erasmus Medical Centre Rotterdam EMC NL
4 University of Zurich UZH CH
5 King’s College London KCL UK
6 Consejo Superior de Investigaciones Cientificas CSIC ES
7 Centre Européen de Recherche en Biologie et Médicine CERBM FR
8 University of Oulu OULU FI
9 Fatebenefratelli Institute IRCCS IT
10 University of Bath UOB UK
11 VU Medical Centre, Amsterdam VUMC NL
12 Empirica Communication and Technology Research EMP DE
13 Combinostics Oy COMBI FI
14 Universitat Pompeu Fabra UPF ES
https://doi.org/10.1371/journal.pone.0245475.t001
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of the final products (glucocorticoid hormones) are potent regulators of glucose and lipid
metabolism. Thus, this represents a central candidate mechanistic player in the aetiology of
multi-morbid symptoms.
3. Inflammatory pathways are a form of cellular response to ELS [19] reflecting activation of
white blood cells in the circulation and peripheral tissues such as the spleen, lymph nodes
and adipose tissue. Inflammatory components may have profound effects on the cardiovas-
cular system, endothelial accumulation and activation of plaques, and adipose tissue metab-
olism, whose dysfunction has been associated with stress-related diseases including
depression, cardiovascular disease and diabetes.
4. Gut microbiome is a major contributor to health and disease [20,21], which plays a key
role in modulating immune, neuroendocrine and behavioural responses to ELS, as proven
mainly in mouse models [28].
In addition to these biological factors, EarlyCause will test the potential moderating role of
key factors such as sex, socioeconomics, and lifestyle in the association between ELS and
multi-morbidity development. Evidence for causality, mediation and moderation will be used
to identify potential targets for intervention acting on the causative mechanisms to reduce the
impact of ELS on multi-morbidity development in high-risk individuals.
Specifically, using longitudinal human data, as well as animal and cellular models we aim to
address the following hypotheses (Table 2).
2. Methods
EarlyCause’s methodology is divided into multiple steps. As shown in Fig 1, the study protocol
aims to triangulate evidence based on (1) longitudinal human data, (2) animal and cellular




Hypothesis 1: Early-life stress, including sexual, physical, psychological abuse and/
or neglect in early life, is a causal factor in the development of PCM multi-
morbidity. Specifically, ELS is a shared risk factor for pre-clinical psychological and
cardiometabolic symptoms in childhood and PCM multi-morbidity in adulthood;
Hypothesis 2: Specific alterations in DNA methylation inflammation,
neuroendocrine function, and/or the gut microbiota mediate the ELS effects on
PCM multi-morbidity;
Hypothesis 3: The association between ELS and PCM is modifiable by lifestyle
factors. We hypothesise positive moderation (prevention) by physical activity,
dietary factors and sleep. In contrast, we hypothesise that the association is
exacerbated by smoking and alcohol consumption;
Hypothesis 4: PCM multi-morbidity is partly heritable and the individual genetic
determinants of depression, and cardiometabolic diseases form a joint genetic
factor of PCM symptoms in child- and adulthood.
Animal model (section 2.2) Hypothesis 1: Exposure to pre- and postnatal stress induces behavioural,
cardiovascular and metabolic changes across adulthood in mice;
Hypothesis 2: The effect of pre- and postnatal stress on the above outcomes
(Hypothesis 1) is mediated by similar epigenetic and molecular changes associated
with PCM multi-morbidity symptoms previously identified in the human model.
Cellular model (section 2.3) Hypothesis 1: Exposure of cells from the brain and peripheral organs to stress-
related insults (cortisol and cytokines) induces cellular changes relevant to PCM
multi-morbidity;
Hypothesis 2: Mechanisms underlying the effect of the stress-related insults on the
aforementioned cell types (Hypothesis 1) are mediated by molecular and gene
expression changes previously identified both in the human and animal models.
https://doi.org/10.1371/journal.pone.0245475.t002
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models, as well as (3) computational bioinformatics and machine learning methods. Con-
cretely, hypotheses on associations between ELS and PCM outcomes, as well as on potential
biological mediators and modifiers, will be generated from the longitudinal human data, and
then translated into experimental designs to be validated in the animal and cellular models,
which will be leveraged to identify the relevant causative mechanisms and molecular pathways
(implementation details are provided in Sections 2.1 & 2.2).
EarlyCause will implement a ‘triangulation’ approach, which will capitalise on the comple-
mentary strengths of epidemiological and genetic methods in humans, experimental animal
and cellular models, and in silico data integration pipelines, as shown in Fig 2. This will enable
us to iteratively and dynamically:
• Apply association analyses and latent modelling to large-scale longitudinal human data on
ELS, resulting in the identification of potential new candidate biomarkers of PCM multi-
morbidity, as well as novel hypotheses on underlying causative mechanisms;
• Apply causal inference methods, including structural equation modelling, Mendelian rando-
misation, and molecular mediation, to infer the causal relationships between ELS, biological
mediators and the multimorbid outcomes;
Fig 1. Schematic overview of the EarlyCause project, that will study the link between ELS (1) and multi-morbidity
(3), as mediated by biological pathways (2). Large-scale life course human data (4), as well as experimental and
computational models, will be used to identify and validate the causative mechanisms.
https://doi.org/10.1371/journal.pone.0245475.g001
Fig 2. Overall methodology of the EarlyCause project, including (A) research platform of harmonised data from
existing resources, research protocols and best practices; (B) triangulation approach, which will capitalise on the
complementary strengths of epidemiological and genetic methods in humans, experimental animal and cellular
models, and in silico data integration pipelines; and (C) expected results such as new biomarkers and clinical
knowledge.
https://doi.org/10.1371/journal.pone.0245475.g002
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• Validate the mechanisms and identify the associated molecular pathways in pre- and postna-
tal animal models, using established cellular models of stress;
• Integrate the identified determinants and molecular markers of ELS into computational
models of multi-morbidity across the life span, and design a proof-of-concept decision sup-
port tool for PCM multi-morbidity risk assessment, by extending an existing single-disease
e-health tool commercialised by EarlyCause partner COMBI (i.e., from the DSF1: Disease
State Fingerprint [29,30] to the MSF: Multi-morbidity State Fingerprint).
2.1 Longitudinal human data
a. Hypothesis-generating analyses of biological markers & environmental modera-
tors. We will leverage harmonized data from a large set of human studies to examine the rela-
tionship between ELS and multi-morbidity across the lifespan, identify potential molecular
markers and quantify the protective vs. exacerbating role of modifiable lifestyle factors. These
datasets together span from pregnancy to old age, including the well-known Avon Longitudi-
nal Study of Parents and Children (ALSPAC), Generation R Study (GenR), Northern Finland
Birth Cohorts (NFBC), UK Biobank, Rotterdam Study, and the Netherlands Study of Depres-
sion and Anxiety (NESDA).
Note that other prominent birth cohorts exist outside of Europe, such as the well-known
Dunedin Study [31], which may be considered for inclusion in later stages of the project if
there is a need to increase the sample size. While the analyses in the child cohorts (e.g., Genera-
tion R, ALSPAC) will focus on life events and circumstances experienced in childhood (up to
age 10), later life events and circumstances—experienced in adolescences and adulthood—will
be taken into account in the adult cohort analysis (e.g., NFBC, Rotterdam Study, NESDA). In
particular, we aim to assess how ELS associates with later PCM multimorbidity by:
i. adjusting for the continuity of life events (i.e., treating later adverse life events as covariates,
allowing us to assess the direct and unique contribution of early exposure to life events);
ii. studying the mediating effect of later life events (i.e., treating later events as a continuum of
earlier risk exposures). In these analyses, we are particularly interested in the mediating
effects of educational attainment, own and parental socioeconomic position (including
income), and substance (ab-)use, measured at a time when the study participants are in
their teenage ages or later.
This will allow us to assess the degree to which early life events are unique risk factors
for PCM multimorbidity or act through a continuum of risk exposures that starts in child-
hood but carries on into adulthood. Furthermore, we will make use of correlational multi-
variate analyses as well as novel latent modelling techniques to model the shared versus the
unique contribution of ELS on multi-morbid outcomes (Fig 3). In these human studies, we
will:
• Define the relationship between ELS and multi-morbidity across the lifespan, by tracking
risk factors of cardiovascular and metabolic disorders in children and adolescents, and the
influence of early life stressors on tracking patterns, drawing a rich dataset of clinical samples
and cohort studies publicly available or through members and collaborators of the consor-
tium. We are currently seeking additional scientists and groups interested in collaborating
with us;
• Identify candidate biological predictors and mediators of ELS effects on multi-morbidity
(epigenetic marks, neuroendocrine function, inflammation, gut microbiome);
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• Quantify the protective or exacerbating role of modifiable lifestyle factors and behaviours,
which include exercise, diet, sleep, smoking and alcohol use in the relationships of ELS with
biological markers and PCM multi-morbidity;
• Provide hypotheses and candidate biomarkers that can be used for causal inference and
mediation studies, as well as in animal and in vitro studies;
b. Causal inference and molecular mediation analyses. To investigate whether ELS rep-
resents a causal risk factor for PCM multi-morbidity, and to what extent biological factors
identified in the hypothesis-generating analyses represent shared non-causal biomarkers of
ELS and PCM multi-morbidity, or point towards causal mediating mechanisms, we will use
multiple approaches. We will apply multiple methods (triangulation) such as Mendelian ran-
domisation, genetic risk score methods and associated sensitivity analyses [32] to infer causal-
ity using population-based human genetic data. Genetic summary measures on ELS and
multi-morbidity will be derived through a meta-analysis of genome-wide association study
(GWAS) data on childhood maltreatment as well as on health outcomes (i.e. depression, type 2
diabetes, and coronary heart disease). More specifically, we will:
• Establish a catalogue of genetic instrumental variables for ELS by performing a GWAS-
meta-analysis across studies of human cohorts involved in EarlyCause and, if possible,
including further studies with relevant data;
• Infer the causal association between postnatal ELS and multi-morbidity development
through Mendelian randomisation and by using both diagnostic criteria and pre-diagnostic
correlates of multimorbid outcomes;
• Establish the molecular mediation of biological markers (DNA methylation, cortisol, inflam-
mation, microbiome) linking ELS exposure to later PCM multi-morbidity.
2.2 Animal and cellular models
a. Modelling ELS in animals for causality assessment. We aim to exploit unique pre-
and postnatal rodent models of stress [27,33] to identify ELS-associated molecular pathways
causally linked to multi-morbid symptoms in adult life. For both models, we will determine
which changes in the epigenome, transcriptome and proteome/metabolome are induced by
Fig 3. Differences between (1) simple multivariate analysis and (2) latent modelling of psycho-cardio-metabolic
multi-morbidity implemented in EarlyCause.
https://doi.org/10.1371/journal.pone.0245475.g003
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ELS exposure across different tissues and biological fluids relevant for PCM symptoms, includ-
ing brain, blood, heart, liver, pancreas and adipose tissue (Fig 4). The purpose will be to iden-
tify common and distinct epigenetic and neuroendocrine factors, immune markers and
molecular pathways dysregulated by ELS in these tissues in the animal models. The observed
alterations will be cross-validated with markers/pathways identified in humans via compara-
tive analyses. Once epigenetic, neuroendocrine, immune and molecular alterations are identi-
fied, their potential reversibility by interventions such as environmental enrichment or
pharmacological compounds will be assessed, based on previous knowledge that enriched life
conditions have beneficial effects on brain and body functions. In a validation step, we will
examine the causal involvement of relevant markers in the aetiology and expression of symp-
toms characteristic of depression, cardiovascular dysfunctions and metabolic alterations by
experimental manipulations in vivo. Specifically, we will:
• Determine and quantify the impact of pre- and postnatal stress on behavioural, cardiovascu-
lar and metabolic functions in adulthood in rodents;
• Examine the effects of intervention and identify moderators relevant for humans;
• Identify epigenetic and molecular pathways associated with symptoms, and test causality in
vivo;
• Assess the specific role of the human gut microbiome as a causative factor for the develop-
ment of PCM multi-morbidity.
In particular, specific behavioural tests, including social interaction test, novel object recog-
nition test, sucrose preference test, open field test, and novelty suppressed feeding test will be
run. Basic metabolic parameters, stress-related endocrine markers (HPA axis) and cardiovas-
cular functions will be assessed in and on tissues. Blood metabolic profiling will be conducted
and components such as high/low-density lipoprotein (HDL/LDL), triglycerides, free fatty
acids, glycerol, C reactive protein will be quantified with appropriate assays. Corticosterone
(HPA-axis activation output) will be measured before and after an acute restraint stress. Blood
pressure and heart rate will be measured by telemetry and tail-cuff, and glucose tolerance,
insulin sensitivity, stress-induced glucose response with the Accu Check Aviva device. Cardiac
functions and vascular tissue will be instead examined by echocardiography and electrocardi-
ography, and 3D reconstruction of cardiac structure will be performed using high-resolution
episcopic microscopy. Moreover, we will also examine the gut microbiome composition in
association with ELS exposure in the animal models and the relationships with other molecular
Fig 4. Overview of the experiments and analyses in rodents to identify molecular pathways linking ELS to PCM
multi-morbidity.
https://doi.org/10.1371/journal.pone.0245475.g004
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alterations, and compare the findings with those in humans. The implication of the human gut
microbiome in the development of multi-morbidity symptoms will also be tested by micro-
biota transplantation experiments into rodents and phenotypic analyses.
b. Cellular models to identify causal molecular mechanisms of ELS-induced multi-mor-
bidity. We aim to uncover causative molecular and biological mechanisms underpinning
ELS-associated multi-morbidity between depression, coronary heart disease and diabetes type
2 associated with ELS by leveraging a variety of human cellular models (Fig 5). Specifically, we
aim to:
• Establish in vitro conditions to mimic stress and metabolic insults in human cell lines and
primary cultures derived from brain, heart, liver, pancreas, and blood immune system;
• Study the effects of ELS on different cellular phenotypes related to depression, coronary
heart disease, and diabetes type 2;
• Test causal mechanisms based on candidate biomarkers obtained from human and animal
studies through molecular manipulations in selected cellular systems;
• Identify the molecular signatures of ELS in the distinct cellular types.
In particular, we will use a coherent, systematic approach to mimic ELS-relevant insults
across a variety of cell lines and primary cells (from male and female donors), isolated from
the human brain (hippocampal progenitor cells, hypothalamic neurons and cortical micro-
glia), heart (cardiomyocytes), liver (hepatocytes), pancreas (pancreatic cells), and blood
immune system (peripheral blood mononuclear cells), in order to identify the molecular pro-
cesses induced by ELS that influence cellular and tissue homeostasis, and resulting in multi-
morbid symptoms. For this purpose, cells will be exposed to candidate stress insults, including
cortisol and interleukin-1 beta (IL-1β),and then both hypothesis-driven and top-hits mecha-
nisms, that are confirmed across the human and animal models, will be investigated in each
cell type (Table 3). Finally, mRNA sequencing analyses will be performed in the best 2–3 cell
types, previously selected as the most representative of ELS-induced PCM multi-morbidity, in
order to identify gene expression changes induced by treatment with stress (cortisol, IL-1β) on
our selected cellular models.
2.3 Computational bioinformatics and machine learning methods. We plan to imple-
ment advanced bioinformatic, statistical and machine learning techniques to integrate and
leverage the findings and determinants derived from human studies and experimental models.
Several types of integration will take place:
Fig 5. Overview of the cellular modelling experiences. SCFAs (Short-chain fatty acids).
https://doi.org/10.1371/journal.pone.0245475.g005
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• Multi-omics integration of molecular interaction networks at different levels (DNA, RNA
and proteins/metabolites) to dissect out the mechanistic chains across tissues;
• Structural equation modelling to model developmental timing and direction of associations,
i.e. direct effects, as well as indirect pathways between variables and lifestyle factors affecting
the pathways;
• Multi-cohort integration for bridging child/adolescent, adult and elderly cohorts and thus
offer a life-course perspective on the link between ELS and multi-morbidity development;
• Machine learning models of multi-morbidity using unsupervised deep learning to simulate
patient-specific trajectories towards multi-morbidity integrating identified biomarkers and
pathways.
Subsequently, a proof-of-concept software will be assembled by integrating the predictive
models within an existing e-health tool commercialised by COMBI; the Disease-State Finger-
print (DSF1). EarlyCause will extend it to account for multi-disease data and associations for
the first time. The obtained tool will be pilot tested by COMBI’s usability experts to assess its
acceptance and potential in future clinical management of multi-morbidities.
2.4 Centralised research platform
The research proposed in EarlyCause is novel, integrating causal inference studies, experimen-
tal models of both pre- and postnatal stress, and new computational approaches for uncover-
ing the causal effects of ELS on multi-morbidity development. The expected results, including
those on the role of epigenetics, microbiome and environmental modifiers, will set the stage
for new studies to generate knowledge and contribute to public health guidelines. We aim to
establish a research-enabling web-platform that will integrate data services, experimental stan-
dards and best practices to support next-generation research on ELS and multi-morbidity. The
EarlyCause web-portal and centralised platform represented in Fig 6 will provide a compre-
hensive support tool to researchers, which will allow them to upload and search data relating
to ELS-induced multi-morbidity. For full FAIR (Findable, Accessible, Interoperable and Re-
usable) compliance, our strategy is to build upon existing life-science/data infrastructures such
as ELIXIR [34] and the EMBL European Bioinformatics Institute.
A key feature of the web-portal will be a rich environment for the discovery and selection of
appropriate data sets and relevant project protocols for further exploration. These functions
will leverage and adapt the existing data hub/portal software framework as developed and used
Table 3. Biochemical and cellular candidate pathways that will be investigated in vitro.
Cell type Biochemical pathways Cellular phenotypes
Hippocampal precursors Doublecortin (DCX), microtubule-associated protein 2 (MAP2),
synaptophysin, Homer1
Neurogenesis; synaptogenesis
Hypothalamic neurons Orthopedia, Neuropeptide Y, retina and anterior neural fold homeobox, ghrelin
receptor
Differentiation
Primary cardiomyocytes G Protein-Coupled Receptor Kinase 2 (GRK2)/cAMP; β-myosin heavy chain
isoform; alpha-myosin
Number of myocytes and mature myocytes, energy
metabolism
Primary hepatocytes Phosphoenol pyruvate carboxykinase; glucose 6- phosphatase; glucokinase;
pyruvate kinase
Gluconeogenesis; glycogen synthesis; glycolysis
Pancreatic EndoC- βH1 Dual Leucine Zipper Kinase; Beta cells transcription factors, PDX1, Nkx 6.1,
MafA
C-peptide secretion, insulin secretion
Peripheral blood mononuclear
cells
Interferon regulatory factors (IRF); JAK-STAT signalling Immune activation relevant to atherosclerosis
https://doi.org/10.1371/journal.pone.0245475.t003
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in such projects as COMPARE [35] and HipScI [36]. The EarlyCause web-portal will be linked
to ELIXIR’s “core” and “deposition” databases, notably the European Nucleotide Archive [37]
(ENA) and European Genome-phenome Archive [38] (EGA) for fully open and controlled
access molecular data, respectively, as well as BioSamples [39] for sample-related data, such as
ELS exposure, rodent model stress descriptors, and Biostudies [40] for a variety of assay data
types, such as rodents behavioural data and metabolic profiling. For image data, in particular
rodents histology, we will leverage the image database from euro-BioImaging [41].
2.5 Impact assessment and exploitation planning
Since the study of ELS and its effects on multi-morbidity represents a novel research field, the
EarlyCause consortium will perform a thorough impact evaluation, spanning socioeconomics,
healthcare practice, prevention strategies, as well as technology and market analysis. The anal-
ysis will be built upon the ASSIST tool-kit, which will use quantitative input from literature-
and expert-informed data, established socioeconomic models and Monte-Carlo simulation, to
perform a qualitative analysis for different stakeholders, e.g. users, beneficiaries, payers, tech-
nologists, organisations, or health-systems. The experience obtained in the impact assessment
of the C3-Cloud EU project [42], which developed clinical decision supports for the manage-
ment of multimorbid chronic patients, will strengthen these activities. For healthcare practice,
ex-ante scenarios will be designed for three countries (Germany, Spain and the UK) and com-
pared to as-is situations to assess the potential impact of the research findings (new biomark-
ers, causal mechanisms, specific role of modifiers such as microbiome) on multi-morbidity
screening and prevention. The resulting evidence-based impact assessment will contribute to
the accelerated diffusion of project results and their acceptance by the social care, healthcare,
and policy communities and facilitate future research activities.
2.6 Ethics and dissemination
The study has been approved by the Ethics Board of the European Commission. The results
will be published in peer-reviewed academic journals, and disseminated to and communicated
with clinicians, patient organisations and media.
3. Discussion
Overall, EarlyCause will explore new territories at the interface of fundamental and clinical
research by addressing the question of how ELS biologically impacts PCM multi-morbidity
Fig 6. Overview of the EarlyCause centralised research platform, which will allow us to upload, search and
manage human and experimental data for investigating ELS-induced multi-morbidity.
https://doi.org/10.1371/journal.pone.0245475.g006
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development. This will provide a rich series of translational research lines for targeting preven-
tion, diagnosis, prognosis, therapy development, and management of PCM multi-morbidity
(Fig 7).
New directions for prevention and diagnosis of ELS-induced multi-
morbidity
EarlyCause aims to create knowledge about the causal impact of ELS on multi-morbidity with
the goal to inform the development of prevention programmes in two main directions. The
first direction concerns the allocation of resources to schemes focused on reducing ELS per se,
such as by providing greater support to high-risk families during pregnancy (e.g. midwife sup-
port, family and school-based programmes), or by increasing resilience to ELS through sup-
porting early emotional, behavioural, and physical regulation in children. The second research
direction concerns the identification of relevant targets for preventing multi-morbidity itself.
Information on (the direction of) causality will allow the most effective primary preventative
strategies to be established. This might focus on promoting lifestyle changes that affect possible
shared causes of multi-morbidity, or treating the primary cause directly, or preventing/treating
all multimorbid conditions together. In addition, knowledge of the role of ELS in PCM multi-
morbidity development can also enhance the identification of multimorbid conditions in
patients screened as having been exposed to ELS and who have already been diagnosed with
one disorder (e.g. depression, but not yet diabetes or coronary heart disease). Furthermore,
EarlyCause will combine ongoing research lines in a unique framework between ELS, inflam-
mation, HPA, and microbiome, which will be scaled-up and extended to include different
‘omics’ levels (e.g. microbiome, genomics, epigenetics). This will open new routes to diagnose
multi-morbidity beyond the simple addition of traditional symptom-based categories, promot-
ing the development of a more biologically-informed nosology of multi-morbidity.
Therapy development
EarlyCause will also promote new research for identifying targets for intervention. A natural
next step will establish whether known drugs can impact the identified biomolecular pathways
(so-called drug repurposing). This will open a host of potential future clinical trials using
repurposed drugs that target these specific mechanisms. Randomised controlled trials are the
Fig 7. Overview of the research directions affected by EarlyCause.
https://doi.org/10.1371/journal.pone.0245475.g007
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gold standard for obtaining evidence on the effects of modifying disease risk processes. How-
ever, traditional drug (repurposing) development has several limitations, including short fol-
low-up, small sample size, and non-representative samples. In this case, our Mendelian
randomisation-based findings on PCM multi-morbidity can have direct implications for drug
repurposing or the identification of unintended drug side effects.
Management of multi-morbidity
Finally, knowledge gathered from EarlyCause will open opportunities for developing new
patient pathways and care models for addressing ELS-related PCM multi-morbidity, comple-
mented with an innovative set of technical solutions for improved clinical decision-making.
The key aim of EarlyCause is also to identify lifestyle factors that dampen or exacerbate the
impact of ELS on PCM multi-morbidity risk. Such knowledge will impact the implementation
of lifestyle changes that can ameliorate symptoms and disease course, particularly amongst
those who have already been exposed to ELS. EarlyCause will therefore improve existing clini-
cal guideline recommendations with economic modelling of benefit and harm. Our ideal end-
point will be to publish evidence to inform the future development of more streamlined and
optimised multi-morbidity care pathways, thus improving decision-making and clinical man-
agement of patients with ELS-related PCM multi-morbidity.
4. Conclusion
In the coming years, EarlyCause will establish extensive research linking human, animal and
cell studies with the aim to clarify how ELS biologically impacts PCM multi-morbidity devel-
opment. The consortium will operate on FAIR data management and open science practices
aiming to impact on the development of diagnostic and new health policies to alert clinicians
on to the damaging effects of ELS and prevent its lifelong consequences.
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